PDS Biotech Presents Updated Results from VERSATILE-002 Phase 2 Clinical Trial at ESMO 2024
Key Findings from the VERSATILE-002 Phase 2 Clinical Trial
PDS Biotech has revealed vital results from the VERSATILE-002 Phase 2 clinical trial. The median overall survival for participants stands at 30 months, indicating significant potential for improved patient outcomes. This data was recently presented at ESMO 2024.
Objective Response and Disease Control Rates
The trial's objective response rate reached 36%, with a disease control rate of 77%. Furthermore, 11 out of 53 patients experienced a remarkable tumor shrinkage of 90-100%, illustrating the efficacy of the treatment.
Further Developments and Future Trials
Looking ahead, PDS Biotech is gearing up for the VERSATILE-003 Phase 3 clinical trial, which promises to build upon these promising results and further evaluate the treatment's effectiveness in a larger patient population.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.